Effect of Soluble CD39 and PD-L1 Levels on Diagnosis and Prognosis of Lung Cancer Patients with Malignant Pleural Effusion

被引：0
|
作者：
Chen, M. [1 ]
Li, X. [2 ]
Wan, B. [1 ]
Zhu, S. [2 ]
Chen, C. [1 ]
Zhang, F. [2 ]
Song, Y. [3 ]
Lv, T. [2 ]
机构：
[1] Southern Med Univ, Sch Clin Med 1, Jinling Hosp, Dept Resp Med, Guangzhou, Peoples R China
[2] Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China
[3] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Soluble PD-L1; Soluble CD39; malignant pleural effusion (MPE);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P36.08
引用
收藏
页码：S437 / S438
页数：2
相关论文
共 50 条
  • [1] Effect of cancer immunotherapy with CD39/PD-L1 bispecific antibody OriA631-b
    Li, Xiaopei
    Zhang, Yuchen
    Yang, Ze
    Deng, Qi
    Wang, Huajing
    Zhu, Haiyan
    Lu, Ligong
    Li, Xian-Yang
    Qu, Ryan
    He, Xiaowen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [3] Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer
    Wu, Yao-Kuang
    Chen, Kuei-Tien
    Kuo, Yung-Bin
    Huang, Ya-Shu
    Chan, Err-Cheng
    CANCER LETTERS, 2009, 273 (02) : 331 - 335
  • [4] Malignant Pleural Effusion Cell Blocks Are Reliable Resources for PD-L1 Analysis in Advanced Lung Adenocarcinomas
    Nambirajan, A.
    Mahajan, S.
    Gupta, I.
    Gupta, P.
    Gupta, N.
    Jain, D.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S509 - S510
  • [5] PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion
    Tseng, Yen-Han
    Ho, Hsiang-Ling
    Lai, Chiung-Ru
    Luo, Yung-Hung
    Tseng, Yen-Chiang
    Whang-Peng, Jacqueline
    Lin, Yi-Hsuan
    Chou, Teh-Ying
    Chen, Yuh-Min
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : 447 - 453
  • [6] High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
    Hagmeyer, Lars
    Schaefer, Stephan
    Engels, Marianne
    Pietzke-Calcagnile, Anja
    Treml, Marcel
    Herkenrath, Simon-Dominik
    Heldwein, Matthias
    Hekmat, Khosro
    Matthes, Sandhya
    Scheel, Andreas
    Wolf, Juergen
    Buettner, Reinhard
    Randerath, Winfried
    ERJ OPEN RESEARCH, 2021, 7 (01)
  • [7] Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
    Chunnan Liu
    Zhaopei Liu
    Kaifeng Jin
    Han Zeng
    Fei Shao
    Yuan Chang
    Yiwei Wang
    Le Xu
    Zewei Wang
    Yu Zhu
    Weijuan Zhang
    British Journal of Cancer, 2022, 127 : 1718 - 1725
  • [8] Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
    Liu, Chunnan
    Liu, Zhaopei
    Jin, Kaifeng
    Zeng, Han
    Shao, Fei
    Chang, Yuan
    Wang, Yiwei
    Xu, Le
    Wang, Zewei
    Zhu, Yu
    Zhang, Weijuan
    BRITISH JOURNAL OF CANCER, 2022, 127 (09) : 1718 - 1725
  • [9] Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma
    Luo, Cheng-Piao
    Mo, Han-Yue
    Wu, Ling-Ling
    Ma, Yun
    Peng, Ning-Fu
    EUROPEAN JOURNAL OF CANCER, 2017, 71 : 117 - 118
  • [10] PD-L1, VISTA, and CD47 expression and prognosis impact in malignant pleural mesothelioma.
    Herrera, Mercedes
    Ucero, Alvaro C.
    Enguita, Ana Belen
    Carrizo, Nuria
    Yarza, Ramon
    Gomez-Randulfe, Igor
    Bote-de-Cabo, Helena
    Baena, Javier
    Garcia-Lorenzo, Esther
    Zugazagoitia, Jon
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345